Kumar Sreelakshmi Sunil, Kannoth Sudheeran, Nambiar Vivek, Gopinath Siby, Anandakuttan Anandkumar, Umesh Saraf Udit, Unnikrishnan Gopikrishnan, Thevarkalam Meena, Mathai Annamma, Rangaswamy Uday Kumar, Sudhakar Abish
Department of Pharmacy Practice, Amrita School of Pharmacy, Amrita Institute of Medical Sciences, Amrita Viswa Vidyapeetham University, Kochi, 682041, Kerala, India.
Department of Neurology, Amrita Institute of Medical Sciences, Amrita Viswa Vidyapeetham University, Kochi, 682041, Kerala, India.
Neurol Sci. 2025 Apr;46(4):1883-1890. doi: 10.1007/s10072-025-07995-1. Epub 2025 Jan 23.
In this research, we extend our initial study in 2016 of a distinct cohort diagnosed with autoimmune atypical parkinsonism, assessing the long-term effects of immunotherapy over a decade.
To study the long-term effects of immunotherapy in patients with autoimmune atypical parkinsonism over 10 years.
Retrospective Observational Study Design STUDY SETTING: The study was carried out at the Department of Neurology at Amrita Institute of Medical Sciences, Kochi, Kerala. The cohort described in our previous study were followed up using data from EMR or by telecommunication.
The authors utilized 9q-mRS scores to assess the disability scores and Kaplan-Meier life tables, using months as the time scale, to estimate the survival of patients with autoimmune atypical parkinsonism who underwent immunotherapy.
Six out of 10 patients expired, but they experienced a good improvement in their 9q-mRS scores during their treatment. Out of the 4 surviving patients, 3 exhibited outstanding responses to immunotherapy while one maintained stable 9q-mRS over an extended period. Kaplan-Meier survival analysis revealed a mean survival time of 74.7 months and a median of 68 months, with 40% of cases censored.
Immunotherapy significantly improved the disability scores in patients with autoimmune atypical parkinsonism.
在本研究中，我们扩展了2016年对一组诊断为自身免疫性非典型帕金森病患者的初步研究，评估了免疫治疗长达十年的长期效果。
研究免疫治疗对自身免疫性非典型帕金森病患者超过10年的长期效果。
回顾性观察研究设计
该研究在喀拉拉邦科钦市阿姆里塔医学科学研究所神经科进行。我们之前研究中描述的队列通过电子病历数据或电话随访。
作者利用9q改良Rankin量表（mRS）评分评估残疾评分，并使用以月为时间尺度的Kaplan-Meier生存表来估计接受免疫治疗的自身免疫性非典型帕金森病患者的生存率。
10名患者中有6名死亡，但他们在治疗期间9q-mRS评分有明显改善。在4名存活患者中，3名对免疫治疗表现出显著反应，而1名在较长时间内维持9q-mRS稳定。Kaplan-Meier生存分析显示平均生存时间为74.7个月，中位数为68个月，40%的病例被截尾。
免疫治疗显著改善了自身免疫性非典型帕金森病患者的残疾评分。
